Cited by 477HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Shattuck, David L., Miller, Jamie K., Carraway, Kermit L., Sweeney, Colleen·2008·Cancer Research

Open this paper in CoChat — free account

Abstract

Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-5962

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497

Show all 43 references

Sorted by citations

Items 301–400 of 477

Selection Criteria for c-Met-Targeted Therapies: Emerging Evidence for Biomarkers
Goetsch, L., & Caussanel, V. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.67 · Cited by 11
The MET Oncogene Network of Interacting Cell Surface Proteins
Gallo, S., Folco, C. B., & Crepaldi, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413692 · Cited by 10
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors
Liu, D., Jee, J., Drilon, A. E. D. C., Heilmann, A. M., Allen, J. M., Schrock, A. B., Keller-Evans, R. B., & Li, B. T. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0620 · Cited by 11
Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Goel, S., & Krop, I. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0742 · Cited by 10
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Moasser, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1121 · Cited by 9
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., & Moulder, S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200715 · Cited by 10
Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells
Huang, B., Yip, W. K., Wei, N., & Luo, K. Q. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.010 · Cited by 10
Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy
Kaya, B., Laurencia, D., Ayoub, M. F., Azad, M. G., Dharmasivam, M., & Richardson, D. R. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100087 · Cited by 10
Inhibition du récepteur MET : un espoir dans la lutte contre les résistances aux thérapies ciblées ?
Hochart, A., Leblond, P., Bourhis, X. L., Meignan, S., & Tulasne, D. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.10.014 · Cited by 9
Hepatocyte growth factor‑induced mesenchymal‑epithelial transition factor activation leads to insulin‑like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells
Liu, R., Tang, W., Han, X., Geng, R., Wang, C., & Zhang, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.9414 · Cited by 9
Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth
Wong, J. S., Warbrick, E., Vojtesek, B., Hill, J., & Lane, D. P. (2013) · Oncotarget · doi:10.18632/oncotarget.1075 · Cited by 9
EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma
Chan, E., Alkhasawneh, A., Duckworth, L. V., Aijaz, T., Toro, T. Z., Lu, X., Hughes, S. J., Collinsworth, A., & George, T. J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.09 · Cited by 9
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies
Ayoub, N. M., Ibrahim, D. R., & Alkhalifa, A. E. (2021) · Medical Oncology · doi:10.1007/s12032-021-01596-6 · Cited by 8
Integration of Genomic Profiling and Organoid Development in Precision Oncology
Yoon, H., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010216 · Cited by 9
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses
Langut, Y., Edinger, N., Flashner-Abramson, E., Melamed‐Book, N., Lebendiker, M., Levi‐Kalisman, Y., Klein, S., & Levitzki, A. (2017) · Oncotarget · doi:10.18632/oncotarget.15733 · Cited by 8
The HGF/MET Signaling and Therapeutics in Cancer
Thewke, D. P., Kou, J., Fulmer, M. L., & Xie, Q. R. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-7296-3_8 · Cited by 8
Intracellular Delivery of siRNAs Targeting AKT and ERBB2 Genes Enhances Chemosensitization of Breast Cancer Cells in a Culture and Animal Model
Fatemian, T., Moghimi, H. R., & Chowdhury, E. H. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090458 · Cited by 9
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval
Sahota, T., Dota, C., Vik, T., Yan, W., Verheijen, R. B., Walker, S. R., Li, Y., Goldwater, R., Ghiorghiu, D. C., Mellemgaard, A., et al. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.896 · Cited by 8
Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis
Tsujio, G., Maruo, K., Yamamoto, Y., Sera, T., Sugimoto, A., Kasashima, H., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09681-3 · Cited by 8
Cell Cycle Regulatory Proteins in Breast Cancer: Molecular Determinants of Drug Resistance and Targets for Anticancer Therapies
Ahmad, A., Wang, Z.-W., Ali, R., Bitar, B., Logna, F., Maitah, M., Bao, B., Ali, S., Kong, D., Li, Y.-W., et al. (2012) · InTech eBooks · doi:10.5772/24272 · Cited by 6
Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer
Tajima, J. Y., Futamura, M., Gaowa, S., Mori, R., Tanahashi, T., Tanaka, Y., Matsuhashi, N., Takahashi, T., Yamaguchi, K., Miyazaki, T., et al. (2017) · Journal of Cancer · doi:10.7150/jca.20266 · Cited by 8
Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma
He, C., Wang, X., Chiou, Y., Basappa, B., Zhu, T., Pandey, V., & Lobie, P. E. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07387-5 · Cited by 7
Evidence for cytoprotective autophagy in response to HER2-targeted monoclonal antibodies
Elshazly, A. M., Elzahed, A. A., & Gewirtz, D. A. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002048 · Cited by 7
The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
Sanz-Álvarez, M., Martı́n-Aparicio, E., Luque, M., Zazo, S., Martínez‐Useros, J., Eroles, P., Rovira, A., Albanell, J., Madoz‐Gúrpide, J., & Rojo, F. (2021) · Cancers · doi:10.3390/cancers13112778 · Cited by 7
The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer
Lan, S., Wu, S., Raghavaraju, G., Chow, N., & Liu, H. (2013) · InTech eBooks · doi:10.5772/53718 · Cited by 7
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.57 · Cited by 7
Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?
Lin, N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0720-7 · Cited by 7
MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
Takumi, Y., Arai, S., Suzuki, C., Fukuda, K., Nishiyama, A., Takeuchi, S., Sato, H., Matsumoto, K., Sugio, K., & Yano, S. (2022) · Cancer Medicine · doi:10.1002/cam4.5342 · Cited by 7
Anticorps et tumeurs solides
Bodmer, A., Goetsch, L., Favet, L., Bailly, C., Corvaı̈a, N., & Dietrich, P. (2009) · médecine/sciences · doi:10.1051/medsci/200925121090 · Cited by 7
Molecular Targeting Therapy and Biomarker for Advanced Gastric Cancer
Shitara, K. (2012) · Journal of Physical Chemistry & Biophysics · doi:10.4172/2161-0398.1000107 · Cited by 6
Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report
Zhou, L. Q., Ren, Y., Wang, X., Miao, D.-L., Lizaso, A., Li, H., Han‐Zhang, H., Qian, J., & Yang, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s206732 · Cited by 6
Identifying Responders to Trastuzumab Therapy in Breast Cancer
Brügmann, A. H., & Sørensen, B. S. (2011) · Future Oncology · doi:10.2217/fon.11.44 · Cited by 6
Prognostic Significance of Mesenchymal–Epithelial Transition in Triple-Negative Breast Cancers
Gao, H., Yang, C.-Q., Cheng, M., Zhu, T., Yang, M., Zhang, L., & Wang, K. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.04.021 · Cited by 6
Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
Pereira, P. M. R., Norfleet, J., Lewis, J. S., & Escorcia, F. E. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244897 · Cited by 6
Current Understanding of Drug Resistance Mechanisms and Therapeutic Targets in HER2 Overexpressing Breast Cancers
Ahmad, A., & Sarkar, F. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5647-6_15 · Cited by 6
Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug ResistancePreprint
Lamballe, F., Ahmad, F., Vinik, Y., Castellanet, O., Daian, F., Müller, A., Köhler, U. A., Bailly, A.-L., Josselin, E., Castellano, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.22.164418 · Cited by 6
The role of genetics and epigenetics in breast cancer: A comprehensive review of metastasis, risk factors, and future perspectives
Chai, Y., & Shi, Y. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101268 · Cited by 7
Adaptive responses to antibody based therapy
Rodems, T. S., Iida, M., Brand, T. M., Pearson, H. E., Orbuch, R. A., Flanigan, B. G., & Wheeler, D. L. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.001 · Cited by 6
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
Cecchi, F., Rex, K. L., Schmidt, J., Vocke, C. D., Lee, Y. H., Burkett, S. S., Baker, D., Damore, M. A., Coxon, A., Burgess, T. L., et al. (2023) · Cancers · doi:10.3390/cancers15020460 · Cited by 5
The MET Receptor Family
Gao, C., & Woude, G. F. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-11888-8_8 · Cited by 5
Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy
Kumar, C., Pareri, A. U., & Koijam, A. S. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210903152354 · Cited by 5
On the Road to Combinations of Targeted Therapies: PPM1H Phosphatase as a Suppressor of Trastuzumab Resistance
Aceto, N., & Bentires‐Alj, M. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0185 · Cited by 5
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer
Strickler, J. H., Raimbourg, J., Cohen, J. E., Ghiringhelli, F., Sharma, M. R., Kitagawa, C., Lee, K. H., O’Neil, B. H., de Miguel, M., Saâda-Bouzid, E., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3597 · Cited by 4
Pre-Adaptive States and Evolutionary Trajectories in Breast Cancer Drug Resistance: From Drug-Tolerant Persisters to Clonal Evolution
Choi, H. Y., Park, M. G., LEE, S., Hwang, J., Choi, H.-C., & Hah, Y. (2026) · Cells · doi:10.3390/cells15090756 · Cited by 4
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer
Naguib, E. M., Ismail, E., Badran, D., SHERIEF, M. H., & El-Abaseri, T. B. (2024) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-024-00250-2 · Cited by 4
Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming
Fang, W. B., Kozai, Y., Acevedo, D. S., Brodine, R., Gorrepati, H. S., Arviso, N., Cote, P., Thompson, A., Gerdes, Z., Espinoza, A., et al. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2535824 · Cited by 4
Trastuzumab-Resistance and Breast Cancer
Dokmanovic, M., & Jin, W. (2011) · InTech eBooks · doi:10.5772/20936 · Cited by 4
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer
Nahta, R. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_7 · Cited by 3
Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.
Jaques, R., Xu, S., & Matsakas, A. (2020) · PubMed · doi:10.14670/hh-18-221 · Cited by 4
Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy
Kim, J.-S., Kim, M. Y., & Hong, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115975 · Cited by 3
Metabolic hallmarks of trastuzumab resistance
Martín-Castillo, B., Verdura, S., Llop‐Hernández, À., Lupu, R., Cuyàs, E., & Menéndez, J. A. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2532394 · Cited by 3
Application of Biological Study for Met Expression to Cancer Therapy
Osada, S., & Yoshida, K. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611009010058 · Cited by 3
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk
Ma, Z., Li, T. X., Fu, W., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00012-2 · Cited by 3
Transcriptomics analyses reveal the effects of Pentagamaboronon-0-ol on PI3K/Akt and cell cycle of HER2+ breast cancer cells
Hermawan, A., Wulandari, F., Utomo, R. Y., Susidarti, R. A., Kirihata, M., & Meiyanto, E. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101847 · Cited by 3
It’s all in for the HER family in tumorigenesis
Lee, M. K., IV, Sharma, A., & Czerniecki, B. J. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.146 · Cited by 3
Targeting multiple pathways in breast cancer
Gagliato, D. D. M., & Gonzalez-Angulo, A. M. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.66 · Cited by 3
Advances in the Scientific Evaluation of Bladder Cancer and Molecular Basis for Diagnosis and Treatment
Persad, R. A., & Ranasinghe, W. (2013) · InTech eBooks · doi:10.5772/56665 · Cited by 3
Resistance to HER2-Targeted Therapy
Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_2 · Cited by 3
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer
Vafaei, R., Khaki, Z., Salehi, M., Jalili, N., Esmailinejad, M. R., Muhammadnajad, A., Nassiri, S. M., Vajhi, A., Kalbolandi, S. M., Mirzaei, R., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01354-7 · Cited by 3
Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer
Vincken, R., Pasco, S. T., Steri, V., Bozal‐Basterra, L., van IJcken, W. F. J., Carracedo, A., Huylebroeck, D., Moasser, M. M., & Ruiz-Sáenz, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118898 · Cited by 2
Handbook of HER2-targeted agents in breast cancer
Álvarez, R. H., Cortés, J., Mattos‐Arruda, L. D., Falzon, M., Fasolo, A., Gandy, M., Gianni, L., Harbeck, N., Piccart, M. J., Zambelli, S., et al. (2013) · doi:10.1007/978-1-907673-94-8 · Cited by 2
Tigilanol Tiglate-Induced Changes in Secretome Profiles Alter C-Met Phosphorylation and Cell Surface Protein Expression in H357 Head and Neck Cancer Cells
Antwi, F. D., Awad, T., Larin, M., Heesom, K. J., Lewis, P. A., Reddell, P. W., Poghosyan, Z. P., Dewitt, S., Moseley, R., & Knäuper, V. (2024) · Cells · doi:10.3390/cells13110982 · Cited by 2
Double trouble: how c-MET and HER2 fuel bladder cancer progression
Naguib, E. M., Ismail, E., Badran, D. I., SHERIEF, M. H., & El-Abaseri, T. B. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00618-y · Cited by 2
Resistance to HER2-Targeted Therapy in HER2+ Breast Cancer
Kessler, E., & Elias, A. (2012) · Clinical Medicine Reviews in Women s Health · doi:10.4137/cmrwh.s3272 · Cited by 2
Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer
Hsu, J. L., & Hung, M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_3 · Cited by 2
Resistance to Anti-Cancer Therapeutics
Woyach, J. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-23637-3_5 · Cited by 2
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview
Crucitta, S., Cucchiara, F., Sciandra, F., Cerbioni, A., Diodati, L., Rafaniello, C., Capuano, A., Fontana, A., Fogli, S., Danesi, R., et al. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210804100547 · Cited by 2
Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics
Smider, V. V. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7654-2_9 · Cited by 2
The role of next‐generation sequencing in the examination of signaling genes in Brca1/2‐negative breast cancer cases
Çine, N., Ugurtas, C., Gökbayrak, M. E., Aydın, D., Demir, G., Kuru, S., Akkoyunlu, D. S., KESKİN, S. E., Şimşek, T., Çabuk, D., et al. (2022) · Annals of Human Genetics · doi:10.1111/ahg.12488 · Cited by 1
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer
Cortesi, M., Bravaccini, S., Ravaioli, S., Petracci, E., Angeli, D., Tumedei, M. M., Balzi, W., Pirini, F., Zanoni, M., Possanzini, P., et al. (2024) · Cancers · doi:10.3390/cancers16223752 · Cited by 1
The ERBB Family of Receptor Tyrosine Kinases: Key Players in Cancer
Garcia, D. D., Marrocco, I., Romaniello, D., & Uribe, M. L. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_2 · Cited by 1
MET : nouvelle cible, nouvelles approches combinatoires
Serrate, C., Watson, S., & Vignot, S. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1376 · Cited by 1
Molecular therapies of colorectal cancer: where will we go from here?
Prager, G. W. (2013) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-013-0108-6 · Cited by 1
Signalling Pathways in Glioma-Propagating Cells
Koh, L., & Toh, T. B. (2016) · Cell Biology Research & Therapy · doi:10.4172/2324-9293.s1-003 · Cited by 1
Échappement tumoral aux inhibiteurs de HER2 : théorie de la sédimentation
Campone, M., Frenel, J., André, F., Bachelot, T., & Juin, P. P. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1591 · Cited by 1
Novel Non–HER2-targeted Therapies in HER2+ Breast Cancer
Sharifi, M. N., & O'Regan, R. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-58122-6.00012-x · Cited by 1
Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination
Modica, C., Cortese, M., Bersani, F., Lombardi, A. M., Napoli, F., Righi, L., Taulli, R., Basilico, C., & Vigna, E. (2023) · Cancers · doi:10.3390/cancers15102742 · Cited by 1
A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
Church, D. N., & Price, C. G. A. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s35 · Cited by 1
Clinical Implications of Molecular Heterogeneity of Gastric Cancer
Hudler, P., & Komel, R. (2017) · InTech eBooks · doi:10.5772/intechopen.69775 · Cited by 1
S-(−)-Oleocanthal as a c-Met receptor tyrosine kinase inhibitor and its application to synergize targeted therapies and prevent breast cancer recurrence
Sayed, K. A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819528-4.00037-7 · Cited by 1
Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity
Chegu, A., Panikar, S. S., & Pereira, P. M. R. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.03.004 · Cited by 1
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
McDermott, M. S. J. (2012) · Arrow@dit (Dublin Institute of Technology) · Cited by 1
Endocytic downregulation of the oncoproteins ErbB2 and ErbB3
Szymańska, M. (2016) · NORA - Norwegian Open Research Archives · Cited by 1
Discovery and Function of the HGF / MET and the MSP / RON Kinase Signaling Pathways in Cancer
Benvenuti, S., Milan, M., & Comoglio, P. M. (2018) · Wiley eBooks · doi:10.1002/9781119300229.ch1 · Cited by 1
Multi-scale based software for effective analysis of anticancer drug efficacy in a computer simulated target environment
Sheraton, V. M. (2019) · doi:10.32657/10356/105587 · Cited by 1
Strategies to ‘Hydrophobize’ Systemic siRNA Vectors and Selectively Inhibit mTORC2 in Breast Tumors Through RNA Interference
Werfel, T. A. (2017) · Cited by 1
Understanding the effects of therapeutic HER2 antibodies trastuzumab and pertuzumab on HER2-mediated cell signaling
Maadi, H. (2020) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-74bb-e058 · Cited by 1
HER2 pozitif metastatik meme kanserinde PTEN, P27 ve PI3K ekspresyonunun prediktif ve prognostik önemi
Okutur, S. K. (2011) · Istanbul Science University (Istanbul Bilim University)
Emerging Targeted Agents for HER2-Positive Breast Cancer
Zardavas, D., & Piccart, M. J. (2013) · doi:10.1007/978-1-907673-94-8_6
NUCLEAR TRANSLOCATION OF MET VIA INTERNET MECHANISM
Chen, M. (2014) · Digital Commons-TMC (Texas Medical Center)
Resistance to Anticancer Antibodies: From Mechanisms to Solutions
Reslan, L., & Dumontet, C. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7654-2_1
ErbB2 (HER2)-positives Mammakarzinom
Kast, K., & Distler, W. (2010) · Der Gynäkologe · doi:10.1007/s00129-010-2529-1
Determining the Role of Autophagy in HER2/neu-Induced Mammary Tumor Dormancy and Recurrence
Dwyer, S. (2013) · Scholarly Commons (University of Pennsylvania)
Tamoxifen resistance in breast cancer : a proteomic approach
Phillips, E. (2012) · University of Birmingham Institutional Research Archive (University of Birmingham)
BASIS FOR TARGETING MET ACTIVATION MEDIATED RESISTANCE TO PI3K INHIBITION IN BREAST CANCER
Gonzalez-Angulo, A. M. (2013) · Digital Commons-TMC (Texas Medical Center)
Optimizing the Management of Metastatic HER2-Positive Breast Cancer
Goel, S., & Tolaney, S. M. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-015-0191-2
A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer
Lindemann, K. Y., Harbeck, N., Lengyel, E. R., & Resau, J. H. (2008) · The Scientific World JOURNAL · doi:10.1100/tsw.2008.110
Mechanisms of resistance to EGFR inhibitors in colorectal cancers
Dhillon, T. (2014) · Colorectal Cancer · doi:10.2217/crc.14.37
Y-box binding protein-1 is essential for the growth and survival of HER2 over-expressing breast cancers and mediates trastuzumab resistance by inducing CD44
Dhillon, J. (2010) · cIRcle (University of British Columbia) · doi:10.14288/1.0069973
Nous mecanismes de resistència primària al trastuzumab (Herceptin): bases moleculars per a la determinació d'un nou subtipus de càncer de mama (Basal/ErbB2+)
Oliveras‐Ferraros, C. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Authors: Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C.
Affiliations: UC Davis Comprehensive Cancer Center (US)
ORCID: Carraway, Kermit L.
Sweeney, Colleen
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2008-03-01
Volume: 68
Issue: 5
Pages: 1471-1477
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-07-5962
OpenAlex: W2027684043
Cited by: 473
References: 43
Citations by year: 2026: 6 · 2025: 18 · 2024: 12 · 2023: 30 · 2022: 18 · 2021: 22 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 24 · 2016: 26 · 2015: 33 · 2014: 37 · 2013: 41 · 2012: 42
FWCI: 14.78
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA123541, R01CA118384, R01CA123541, CA118384)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: MET receptor tyrosine kinase, trastuzumab resistance, HER2-positive breast cancer, combination therapy, MET inhibition, HER2-targeted therapy, drug resistance
MeSH terms: Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Breast, Breast Neoplasms, Humans, Models, Biological, Phosphorylation, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks